Compare Crispr Therapeutics AG (CRSP) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SiTime Corporation — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while SiTime Corporation trades at $630.25 (market cap $18.72B). The key difference: SiTime Corporation is far larger — about 3.8× Crispr Therapeutics AG's market cap, and SiTime Corporation is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | SITM | |
|---|---|---|
Market Cap | $4.97B | $18.72B |
Sector | Health | Technology |
52-Week High | $76.78 | $901.60 |
52-Week Low | $44.34 | $190.16 |
Enterprise Value | $3.32B | $17.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SITM trades at $602.55, down 4.2% over 24 hours, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth and expanding gross margins, driven by AI infrastructure demand and the completed Renesas acquisition. Analyst consensus remains unanimously bullish with a $743.75 price target, though negative net income and high valuation ratios present fundamental concerns.
Outlook is mixed: robust AI-driven growth and strategic acquisitions offer upside, but profitability challenges and bearish technicals near-term pose risks. Investors should weigh strong analyst support against cash flow volatility and execution risks in integrating new assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
